Osmotic Demyelination Syndrome Resulting from an Unexpected Response to Tolvaptan in a Patient with Heart Failure / 대한내과학회지
Korean Journal of Medicine
;
: 62-65, 2017.
Article
Dans Coréen
| WPRIM
| ID: wpr-194638
ABSTRACT
Hyponatremia is commonly encountered in patients with heart failure and has a poor prognosis. Tolvaptan, a novel selective vasopressin V2 receptor blocker, has received attention as an effective drug for treating the syndrome of inappropriate antidiuretic hormone secretion and hypervolemic hyponatremia. However, the safety of tolvaptan in the treatment of hyponatremia is not clear. We experienced a 78-year-old woman with a history of heart failure, atrial fibrillation, and hyponatremia who developed osmotic demyelination syndrome as an unexpected response to treatment with tolvaptan.
Texte intégral:
Disponible
Indice:
WPRIM (Pacifique occidental)
Sujet Principal:
Pronostic
/
Fibrillation auriculaire
/
Maladies démyélinisantes
/
Récepteurs à la vasopressine
/
Coeur
/
Défaillance cardiaque
/
Hyponatrémie
Type d'étude:
Étude pronostique
Limites du sujet:
Adulte très âgé
/
Femelle
/
Humains
langue:
Coréen
Texte intégral:
Korean Journal of Medicine
Année:
2017
Type:
Article
Documents relatifs à ce sujet
MEDLINE
...
LILACS
LIS